• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Infectious Disease

Second-line TAF-based ART improves viral suppression in pediatric HIV

byZhenyu Li, MScandKiera Liblik
June 4, 2025
in Infectious Disease, Pediatrics
Reading Time: 3 mins read
HIV care collage: an engraved immune cell inside a ring of torn blue paper, with a small teal shield and a teal ribbon
Share on FacebookShare on TwitterShare on LinkedIn

1. In this randomized controlled trial (CHAPAS-4), tenofovir alafenamide fumarate (TAF) with emtricitabine showed superior viral suppression at 96 weeks compared to standard care (abacavir or zidovudine with lamivudine) in children living with human immunodeficiency virus (HIV) in Africa.

2. Dolutegravir as an anchor drug outperformed ritonavir-boosted lopinavir and atazanavir, with a higher rate of viral suppression and fewer severe adverse events.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The mainstay of treatment for HIV in both children and adults is antiretroviral therapy (ART). Access to HIV care is improving on a global scale, with non-nucleoside reverse transcriptase inhibitor (NNRTI)–based treatment recommended as first-line. When first-line therapy fails, it is unclear which drugs have the best safety in efficacy outcomes in the pediatric population. Accordingly, this randomized controlled trial evaluated second-line antiretroviral therapy in African children with HIV who had failed first-line NNRTI–based treatment. Children were randomized to receive either TAF with emtricitabine or standard care with abacavir or zidovudine plus lamivudine, along with one of four anchor drugs: dolutegravir, ritonavir-boosted darunavir, ritonavir-boosted atazanavir, or ritonavir-boosted lopinavir. TAF and dolutegravir led to better viral suppression and growth outcomes. Strengths included a large sample size and high retention. Limitations included limited availability of pediatric TAF and regional generalizability. In summary, this study demonstrated that TAF-based ART is an effective and safe second-line HIV treatment in the pediatric population.

Click to read the study in the NEJM (New England Journal of Medicine)

Relevant Reading: Assessment of Second-Line Antiretroviral Regimens for HIV Therapy in Africa Leukodystrophy

RELATED REPORTS

Use of long-acting broadly neutralizing antibodies may delay human immunodeficiency virus (HIV) rebound following discontinuation of antiretroviral therapy

Lower levels of education and place of birth were associated with non-admission to the intensive care unit in Sweden during COVID-19 pandemic

FDA approvedFor HIV: Idvynso (doravirine and islatravir), Apr 20, 2026→

In-Depth [randomized controlled trial]: This open-label, randomized controlled trial (CHAPAS-4) assessed second-line ART options in 919 African children aged 3 to 15 years living with HIV who experienced virologic failure on first-line NNRTI–based regimens. Participants were randomized in a two-by-four factorial design to receive either TAF-emtricitabine or standard care (abacavir–lamivudine or zidovudine–lamivudine) as the nucleoside reverse transcriptase inhibitor (NRTI) backbone. Additionally, they were assigned one of four anchor drugs: dolutegravir, ritonavir-boosted darunavir, ritonavir-boosted atazanavir, or ritonavir-boosted lopinavir. The primary outcome was achieving viral suppression, defined as HIV RNA <400 copies/mL, at 96 weeks. Viral suppression was observed in 89.4% of participants receiving TAF–emtricitabine versus 83.3% in the standard care group (adjusted difference, 6.3 percentage points; 95% Confidence Interval [CI], 2.0–10.6; p=0.004), meeting criteria for both noninferiority and superiority. Among anchor drugs, dolutegravir led to the highest suppression rate at 92.0%, compared to 80.7% with ritonavir-boosted lopinavir and 84.3% with ritonavir-boosted atazanavir. Dolutegravir was significantly superior to the combined comparator group of lopinavir and atazanavir (adjusted difference, 9.7 percentage points; 95% CI, 4.8–14.5; p<0.001). Ritonavir-boosted darunavir showed moderate benefit (88.3%) but did not meet the pre-specified threshold for superiority (p=0.04). Growth outcomes also favored TAF–emtricitabine, with modest but statistically significant improvements in weight-for-age, height-for-age, and BMI-for-age z scores. Adverse event rates were similar across groups: grade 3 or 4 events occurred in 13.8% of participants overall, and serious adverse events in 3.2%. One participant died, though the cause was unrelated to treatment. These results support the use of TAF–emtricitabine and dolutegravir as preferred second-line options in pediatric HIV care, offering effective viral suppression and acceptable safety profiles.

Image: PD

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: antiretroviral therapyARTHIVinfectious diseasepediatric HIVTAFTenofovir alafenamide
Previous Post

Midlife weight loss is associated with decreased risk of mortality and chronic disease

Next Post

2 Minute Medicine: Pharma Roundup – Perioperative Immunotherapy Efficacy, Expanded Prostate Cancer Indication, Rapid Subcutaneous Myeloma Administration, and Regulatory Compliance Findings [June 4 2025]

RelatedReports

A circular calendar divided into sections, with a blue pill resting on one section and representations of HIV particles surrounding it, symbolizing HIV treatment adherence.
Chronic Disease

Use of long-acting broadly neutralizing antibodies may delay human immunodeficiency virus (HIV) rebound following discontinuation of antiretroviral therapy

September 24, 2026
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Emergency

Lower levels of education and place of birth were associated with non-admission to the intensive care unit in Sweden during COVID-19 pandemic

September 1, 2026
HIV care collage: a smiling middle-aged man with an awareness ribbon pinned to his shirt beside a sprig of olive leaves
Infectious Disease

Maternal engagement in HIV care associated with pediatric viral suppression

August 28, 2026
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Chronic Disease

Hematologic inflammatory indices may predict prognosis in younger patients with COVID-19 but not older patients

August 4, 2026
Next Post
2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]

2 Minute Medicine: Pharma Roundup – Perioperative Immunotherapy Efficacy, Expanded Prostate Cancer Indication, Rapid Subcutaneous Myeloma Administration, and Regulatory Compliance Findings [June 4 2025]

Blood pressure collage: a large artery cross-section ring, a tipped salt cellar spilling crystals and a plain wristwatch

Hypotension- and hypertension-avoidance strategies may yield similar neurocognitive outcomes following noncardiac surgery

Stroke care collage: an older man in a plaid shirt beside a brain slice with one shaded area and a textured therapy ball

Impaired lipoprotein cholesterol ratio is associated with cognitive impairment in patients with stroke

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Large genetic association study identifies additional Alzheimer disease risk loci and candidate pathways
  • Pelacarsen lowers lipoprotein(a) but does not reduce major cardiovascular events in patients with established cardiovascular disease
  • Durvalumab plus enfortumab vedotin was approved for perioperative treatment of muscle-invasive bladder cancer
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.